Latham & Watkins represented Affer in the transaction. Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has announced that it has entered into a definitive agreement...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Mesoblast in the transaction. Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in stem cell medicines for inflammatory diseases, has announced that it has...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented BridgeBio in the transaction. BridgeBio Pharma (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, executed a...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the transaction. Minerva Surgical, Inc. (Minerva Surgical), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB),...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Warby Parker Inc. in the transaction. Warby Parker Inc. executed its direct listing on the New York Stock Exchange under the ticker symbol...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented eFFECTOR in the transaction, eFFECTOR Therapeutics, Inc. (eFFECTOR), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Wachtell, Lipton, Rosen & Katz represented Ginkgo Bioworks, while White & Case LLP advised Soaring Eagle Acquisition Corp. in the transaction....
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented the underwriters in the offering. Rain Therapeutics Inc. (Rain), a clinical-stage company developing precision oncology therapeutics, executed its initial public offering...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Treace Medical Concepts, Inc. in the offering. Treace Medical Concepts, Inc. (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a...
You must be a Standard 1 Year member to access this content.
